FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Animals (Basel) / Is the Use of Bisphosphonates Putting Horses at Risk? An Ost...
Animals : an open access journal from MDPI2022; 12(13); doi: 10.3390/ani12131722

Is the Use of Bisphosphonates Putting Horses at Risk? An Osteoclast Perspective.

Abstract: Osteoclasts are unique and vital bone cells involved in bone turnover. These cells are active throughout the individual's life and play an intricate role in growth and remodeling. However, extra-label bisphosphonate use may impair osteoclast function, which could result in skeletal microdamage and impaired healing without commonly associated pain, affecting bone remodeling, fracture healing, and growth. These effects could be heightened when administered to growing and exercising animals. Bisphosphonates (BPs) are unevenly distributed in the skeleton; blood supply and bone turnover rate determine BPs uptake in bone. Currently, there is a critical gap in scientific knowledge surrounding the biological impacts of BP use in exercising animals under two years old. This may have significant welfare ramifications for growing and exercising equids. Therefore, future research should investigate the effects of these drugs on skeletally immature horses.
Get Full Text
Publication Date: 2022-07-03 PubMed ID: 35804621PubMed Central: PMC9265010DOI: 10.3390/ani12131722Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research paper discusses the potential harm that can be caused to horses, particularly those under two years old, from the use of bisphosphonates, a type of drug that could interfere with the function of osteoclasts, essential cells involved in bone development and healing.

Background on Osteoclasts and Bisphosphonates

  • The research paper begins by providing some background on osteoclasts. These are unique and essential cells that are involved in the turnover of bones. These cells function all through a horse’s life, actively participating in growth and remodeling of the skeletal structure.
  • The drug under scrutiny in this paper is bisphosphonates (BPs). These are widely used in medical treatments like osteoporosis. BPs have a significant impact on bone metabolism as they can alter the function of osteoclasts, and thereby the process of bone remodeling.
  • However, the research points out that there could be negative implications from interfering with the normal functioning of osteoclasts. There’s a risk that using BPs could lead to skeletal microdamage and impaired healing, all happening without associated pain that would usually signal a problem.

Potential Risks in Younger, Exercising Horses

  • The research further stress that these potential risks could be even more pronounced in growing and exercising animals. This is mainly because their bone structures are in a faster rate of growth and remodeling.
  • The distribution of BPs in the skeleton is not even; it is determined by the bone’s blood supply and turnover rate. This could mean that some bones may be more affected than others by the use of the drug.
  • It’s outlined that a critical gap currently exists in the scientific understanding of how BPs potentially affect exercising animals, particularly those that are under two years old. The research implies that this could have serious implications for the overall welfare of young, active horses.

Call for Future Research

  • The paper concludes by stating that there is a need for future research to be conducted on this issue. It suggests that future investigations should particularly focus on the effects of BPs on young horses that are still growing, to better understand any potential risks and complications.

Cite This Article

APA
Vergara-Hernandez FB, Nielsen BD, Colbath AC. (2022). Is the Use of Bisphosphonates Putting Horses at Risk? An Osteoclast Perspective. Animals (Basel), 12(13). https://doi.org/10.3390/ani12131722

Publication

Animals : an open access journal from MDPI
ISSN: 2076-2615
NlmUniqueID: 101635614
Country: Switzerland
Language: English
Volume: 12
Issue: 13

Researcher Affiliations

Vergara-Hernandez, Fernando B
  • Department of Animal Science, Michigan State University, 474 S. Shaw Ln, East Lansing, MI 48824, USA.
Nielsen, Brian D
  • Department of Animal Science, Michigan State University, 474 S. Shaw Ln, East Lansing, MI 48824, USA.
Colbath, Aimee C
  • Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, 736 Wilson Ave, East Lansing, MI 48864, USA.

Conflict of Interest Statement

The authors declare no conflict of interest.

References

This article includes 104 references
  1. Martin JT. Historically Significant Events in the Discovery of RANK/RANKL/OPG. World J. Orthop. 2013;4:186–197.
    doi: 10.5312/wjo.v4.i4.186pmc: PMC3801238pubmed: 24147254google scholar: lookup
  2. Allen MR, Burr DB. Bone Growth, Modeling, and Remodeling. 2019. pp. 85–100.
  3. Burr DB. Fifty Years of Bisphosphonates: What Are Their Mechanical Effects on Bone?. Bone 2020;138:115518.
    doi: 10.1016/j.bone.2020.115518pubmed: 32622873google scholar: lookup
  4. Mitchell A, Watts AE, Ebetino FH, Suva LJ. Bisphosphonate Use in the Horse: What Is Good and What Is Not?. BMC Vet. Res. 2019;15:211.
    doi: 10.1186/s12917-019-1966-xpmc: PMC6591999pubmed: 31234844google scholar: lookup
  5. Suva LJ, Cooper A, Watts AE, Ebetino FH, Price J, Gaddy D. Bisphosphonates in Veterinary Medicine: The New Horizon for Use. Bone 2021;142:115711.
    doi: 10.1016/j.bone.2020.115711pubmed: 33141069google scholar: lookup
  6. Boyle WJ, Simonet WS, Lacey DL. Osteoclast Differentiation and Activation. Nature 2003;423:337–342.
    doi: 10.1038/nature01658pubmed: 12748652google scholar: lookup
  7. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A. Osteoclast Differentiation Factor is a Ligand for Osteoprotegerin/Osteoclastogenesis-Inhibitory Factor and is Identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 1998;95:3597–3602.
    doi: 10.1073/pnas.95.7.3597pmc: PMC19881pubmed: 9520411google scholar: lookup
  8. Park-Min KH. Mechanisms Involved in Normal and Pathological Osteoclastogenesis. Cell. Mol. Life Sci. 2018;75:2519–2528.
    doi: 10.1007/s00018-018-2817-9pmc: PMC9809143pubmed: 29670999google scholar: lookup
  9. Whyte MP, Wenkert D, Clements KL, Mcalister WH, Mumm S. Bisphosphonate-Induced Osteopetrosis: Novel Bone Modeling Defects, Metaphyseal Osteopenia, and Osteosclerosis Fractures after Drug Exposure Ceases. J. Bone Miner. Res. 2008;23:1698–1707.
    doi: 10.1359/jbmr.080511pubmed: 18505375google scholar: lookup
  10. Teitelbaum SL. Osteoclasts; Culprits Inflammatory Osteolysis. Arthritis Res. Ther. 2006;8:201.
    doi: 10.1186/AR1857pmc: PMC1526550pubmed: 16356195google scholar: lookup
  11. Bellido T, Plotkin LI, Bruzzaniti A. Bone Cells. 2019. pp. 37–55.
  12. Xu F, Teitelbaum SL. Osteoclasts: New Insights. Bone Res. 2013;1:11–26.
    doi: 10.4248/BR201301003pmc: PMC4472093pubmed: 26273491google scholar: lookup
  13. Holtrop ME, King GJ. The Ultrastructure of the Osteoclast and its Functional Implications. Clin. Orthop. Relat. Res. 1977;123:177–196.
    doi: 10.1097/00003086-197703000-00062pubmed: 856515google scholar: lookup
  14. Robling AG, Daly R, Fuchs RK, Burr DB. Mechanical Adaptation. 2019. pp. 203–233.
  15. Sobacchi C, Frattini A, Guerrini MM, Abinun M, Pangrazio A, Susani L, Bredius R, Mancini G, Cant A, Bishop N. Osteoclast-Poor Human Osteopetrosis Due to Mutations in the Gene Encoding RANKL. Nat. Genet. 2007;39:960–962.
    doi: 10.1038/ng2076pubmed: 17632511google scholar: lookup
  16. Fukumoto S, Martin TJ. Bone as an Endocrine Organ. Trends Endocrinol. Metab. 2009;20:230–236.
    doi: 10.1016/j.tem.2009.02.001pubmed: 19546009google scholar: lookup
  17. Burr DB. Bone Morphology and Organization. 2019. pp. 3–26.
  18. Wolff J. Ueber Die Innere Architectur der Knochen und Ihre Bedeutung Für Die Frage Vom Knochenwachsthum. Arch. Für Pathol. Anat. Und Physiol. Und Für Klin. Med. 1870;50:389–450.
    doi: 10.1007/BF01944490google scholar: lookup
  19. Langdahl B, Ferrari S, Dempster DW. Bone Modeling and Remodeling: Potential as Therapeutic Targets for the Treatment of Osteoporosis. TAMD 2016;8:225–235.
    doi: 10.1177/1759720X16670154pmc: PMC5322859pubmed: 28255336google scholar: lookup
  20. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RGG, Ebetino FH. Novel Insights into Actions of Bisphosphonates on Bone: Differences in Interactions with Hydroxyapatite. Bone 2006;38:617–627.
    doi: 10.1016/j.bone.2005.05.003pubmed: 16046206google scholar: lookup
  21. Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT. Benefits and Risks of Bisphosphonate Therapy for Osteoporosis. J. Clin. Endocrinol. Metab. 2012;97:2272–2282.
    doi: 10.1210/jc.2012-1027pubmed: 22523337google scholar: lookup
  22. Soto SA, Chiappe Barbará A. Bisphosphonates: Pharmacology and Clinical Approach to Their Use in Equine Osteoarticular Diseases. J. Equine Vet. Sci. 2014;34:727–737.
    doi: 10.1016/j.jevs.2014.01.009google scholar: lookup
  23. Rogers MJ, Crockett JC, Coxon FP, Mönkkönen J. Biochemical and Molecular Mechanisms of Action of Bisphosphonates. Bone 2011;49:34–41.
    doi: 10.1016/j.bone.2010.11.008pubmed: 21111853google scholar: lookup
  24. Russell RGG. Bisphosphonates: Mode of Action and Pharmacology. Pediatrics 2007;119:S150–S162.
    doi: 10.1542/peds.2006-2023Hpubmed: 17332236google scholar: lookup
  25. Russell RGG. Bisphosphonates: The First 40 Years. Bone 2011;49:2–19.
    doi: 10.1016/j.bone.2011.04.022pubmed: 21555003google scholar: lookup
  26. Sims NA, Martin TJ. Osteoclasts Provide Coupling Signals to Osteoblast Lineage Cells Through Multiple Mechanisms. Annu. Rev. Physiol. 2020;82:507–529.
    doi: 10.1146/annurev-physiol-021119-034425pubmed: 31553686google scholar: lookup
  27. Jensen PR, Andersen TL, Chavassieux P, Roux JP, Delaisse JM. Bisphosphonates Impair the Onset of Bone Formation at Remodeling Sites. Bone 2021;145:115850.
    doi: 10.1016/j.bone.2021.115850pubmed: 33465485google scholar: lookup
  28. Lin JH. Bisphosphonates: A Review of Their Pharmacokinetic Properties. Bone 1996;18:75–85.
    doi: 10.1016/8756-3282(95)00445-9pubmed: 8833200google scholar: lookup
  29. Daley-Yates PT, Dodwell DJ, Pongchaidecha M, Coleman RE, Howell A. The Clearance and Bioavailability of Pamidronate in Patients with Breast Cancer and Bone Metastases. Calcif. Tissue Int. 1991;49:433–435.
    doi: 10.1007/BF02555856pubmed: 1818770google scholar: lookup
  30. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Porras AG. Clinical Pharmacology of Alendronate Sodium. Osteoporos. Int. 1993;3:13–16.
    doi: 10.1007/BF01623002pubmed: 8298197google scholar: lookup
  31. Yakatan GJ, Poynor WJ, Talbert RL, Floyd BF, Slough CL, Ampulski RS, Benedict JJ. Clodronate Kinetics and Bioavailability. Clin. Pharmacol. Ther. 1982;31:402–410.
    doi: 10.1038/clpt.1982.51pubmed: 6460586google scholar: lookup
  32. Mönkkönen J, Ylitalo P. The Tissue Distribution of Clodronate (Dichloromethylene Bisphosphonate) in Mice. The Effects of Vehicle and the Route of Administration. Eur. J. Drug Metab. Pharmacokinet. 1990;15:239–243.
    doi: 10.1007/BF03190210pubmed: 2147646google scholar: lookup
  33. Lin JH, Chen IW, Duggan DE. Effects of Dose, Sex, and Age on the Disposition of Alendronate, a Potent Antiosteolytic Bisphosphonate, in Rats. Drug Metab. Dispos. 1992;20:473–478.
    pubmed: 1356720
  34. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA. Bisphosphonate Action. Alendronate Localization in Rat Bone and Effects on Osteoclast Ultrastructure. J. Clin. Investig. 1991;88:2095–2105.
    doi: 10.1172/JCI115539pmc: PMC295810pubmed: 1661297google scholar: lookup
  35. Kasting GB, Francis MD. Retention of Etidronate in Human, Dog, and Rat. J. Bone Miner. Res. 1992;7:513–522.
    doi: 10.1002/jbmr.5650070507pubmed: 1615760google scholar: lookup
  36. Cremers S, Papapoulos S. Pharmacology of Bisphosphonates. Bone 2011;49:42–49.
    doi: 10.1016/j.bone.2011.01.014pubmed: 21281748google scholar: lookup
  37. Frith JC, Mönkkönen J, Blackburn GM, Russell RGG, Rogers MJ. Clodronate and Liposome-Encapsulated Clodronate Are Metabolized to a Toxic ATP Analog, Adenosine 5’-(β,γ-Dichloromethylene) Triphosphate, by Mammalian Cells in Vitro. J. Bone Miner. Res. 1997;12:1358–1367.
    doi: 10.1359/jbmr.1997.12.9.1358pubmed: 9286751google scholar: lookup
  38. Freedom of Information Summary Original, New Animal Drug Application, NADA 141-427, Osphos, Clodronate Injection, Horse, for the Control of Clinical Signs Associated with Navicular Syndrome in Horses|FDA Center for Veterinary Medicine|FDA Approved Animal Drug Products. [(accessed on 30 May 2022)]; Available online: https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/923.
  39. Krueger CR, Mitchell CF, Leise BS, Knych HK. Pharmacokinetics and Pharmacodynamics of Clodronate Disodium Evaluated in Plasma, Synovial Fluid and Urine. Equine Vet. J. 2020;52:725–732.
    doi: 10.1111/evj.13244pubmed: 32003488google scholar: lookup
  40. Delguste C, Amory H, Guyonnet J, Thibaud D, Garnero P, Detilleux J, Lepage OM, Doucet M. Comparative Pharmacokinetics of Two Intravenous Administration Regimens of Tiludronate in Healthy Adult Horses and Effects on the Bone Resorption Marker CTX-1. J. Vet. Pharmacol. Ther. 2008;31:108–116.
    doi: 10.1111/j.1365-2885.2007.00936.xpubmed: 18307502google scholar: lookup
  41. Russell RGG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of Action of Bisphosphonates: Similarities and Differences and Their Potential Influence on Clinical Efficacy. Osteoporos. Int. 2008;19:733–759.
    doi: 10.1007/s00198-007-0540-8pubmed: 18214569google scholar: lookup
  42. Maruotti N, Corrado A, Neve A, Cantatore FP. Bisphosphonates: Effects on Osteoblast. Eur. J. Clin. Pharmacol. 2012;68:1013–1018.
    doi: 10.1007/s00228-012-1216-7pubmed: 22318756google scholar: lookup
  43. Wong ASY, Ho ENM, Wan TSM, Lam KKH, Stewart BD. Liquid Chromatography-Mass Spectrometry Analysis of Five Bisphosphonates in Equine Urine and Plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2015;15:1–7.
    doi: 10.1016/j.jchromb.2015.06.020pubmed: 26143477google scholar: lookup
  44. D’Eufemia P, Finocchiaro R, Celli M, Zambrano A, Tetti M, Villani C, Persiani P, Mari E, Zicari A. High Levels of Serum Prostaglandin E2 in Children with Osteogenesis Imperfecta are Reduced by Neridronate Treatment. Pediatr. Res. 2008;63:203–206.
    doi: 10.1203/PDR.0b013e31815efd63pubmed: 18091347google scholar: lookup
  45. Felix R, Bettex JD, Fleisch H. Effect of Diphosphonates on the Synthesis of Prostaglandins in Cultured Calvaria Cells. Calcif. Tissue Int. 1981;33:549–552.
    doi: 10.1007/BF02409488pubmed: 6459147google scholar: lookup
  46. Garganta MD, Jaser SS, Lazow MA, Schoenecker JG, Cobry E, Hays SR, Simmons JH. Cyclic Bisphosphonate Therapy Reduces Pain and Improves Physical Functioning in Children with Osteogenesis Imperfecta 11 Medical and Health Sciences 1103 Clinical Sciences. BMC Musculoskelet. Disord. 2018;19:344.
    doi: 10.1186/S12891-018-2252-Ypmc: PMC6154399pubmed: 30249227google scholar: lookup
  47. Markell R, Saviola G, Barker EA, Conway JD, Dujardin C. What Do We Know About Clodronate Now? A Medical and Veterinary Perspective. J. Equine Vet. Sci. 2020;88:102874.
    doi: 10.1016/j.jevs.2019.102874pubmed: 32303308google scholar: lookup
  48. Xing RL, Zhao LR, Wang PM. Bisphosphonates Therapy for Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. SpringerPlus 2016;5:1704.
    doi: 10.1186/s40064-016-3359-ypmc: PMC5047862pubmed: 27757376google scholar: lookup
  49. Roman-Blas JA, Castañeda S, Largo R, Lems WF, Herrero-Beaumont G. An OA Phenotype May Obtain Major Benefit from Bone-Acting Agents. Semin. Arthritis Rheum. 2014;43:421–428.
    doi: 10.1016/j.semarthrit.2013.07.012pubmed: 24016748google scholar: lookup
  50. Fernández-Martín S, López-Peña M, Muñoz F, Permuy M, González-Cantalapiedra A. Bisphosphonates as Disease-Modifying Drugs in Osteoarthritis Preclinical Studies: A Systematic Review from 2000 to 2020. Arthritis Res. Ther. 2021;23:60.
    doi: 10.1186/s13075-021-02446-6pmc: PMC7898436pubmed: 33618776google scholar: lookup
  51. Park JY, Pillinger MH, Abramson SB. Prostaglandin E2 Synthesis and Secretion: The Role of PGE2 Synthases. Clin. Immunol. 2006;119:229–240.
    doi: 10.1016/j.clim.2006.01.016pubmed: 16540375google scholar: lookup
  52. Frisbie DD, Al-Sobayil F, Billinghurst RC, Kawcak CE, McIlwraith CW. Changes in Synovial Fluid and Serum Biomarkers with Exercise and Early Osteoarthritis in Horses. Osteoarthr. Cartil. 2008;16:1196–1204.
    doi: 10.1016/j.joca.2008.03.008pubmed: 18442931google scholar: lookup
  53. McIlwraith CW, Kawcak C, Baxter GM, Goodrich LR, Valberg SJ. Principles of Musculoskeletal Disease. 2020. pp. 801–874.
  54. Coudry V, Thibaud D, Riccio B, Audigié F, Didierlaurent D, Denoix JM. Efficacy of Tiludronate in the Treatment of Horses with Signs of Pain Associated with Osteoarthritic Lesions of the Thoracolumbar Vertebral Column. Am. J. Vet. Res. 2007;68:329–337.
    doi: 10.2460/ajvr.68.3.329pubmed: 17331024google scholar: lookup
  55. Gough MR, Thibaud D, Smith RKW. Tiludronate Infusion in the Treatment of Bone Spavin: A Double Blind Placebo-Controlled Trial. Equine Vet. J. 2010;42:381–387.
    doi: 10.1111/j.2042-3306.2010.00120.xpubmed: 20636772google scholar: lookup
  56. Mitchell A, Wright G, Sampson SN, Martin M, Cummings K, Gaddy D, Watts AE. Clodronate Improves Lameness in Horses without Changing Bone Turnover Markers. Equine Vet. J. 2019;51:356–363.
    doi: 10.1111/evj.13011pubmed: 30153345google scholar: lookup
  57. Moriyama Y, Nomura M. Clodronate: A Vesicular ATP Release Blocker. Trends. Pharmacol. Sci. 2018;39:13–23.
    doi: 10.1016/j.tips.2017.10.007pubmed: 29146440google scholar: lookup
  58. Lewiecki EM, Miller PD. Renal Safety of Intravenous Bisphosphonates in the Treatment of Osteoporosis. Expert Opin. Drug Saf. 2006;6:663–672.
    doi: 10.1517/14740338.6.6.663pubmed: 17967155google scholar: lookup
  59. Castillo H, Samson-Fang L. Effects of Bisphosphonates in Children with Osteogenesis Imperfecta: An AACPDM Systematic Review. Dev. Med. Child Neurol. 2009;51:17–29.
    doi: 10.1111/j.1469-8749.2008.03222.xpubmed: 19087101google scholar: lookup
  60. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S. Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 2007;22:1479–1491.
    doi: 10.1359/jbmr.0707onjpubmed: 17663640google scholar: lookup
  61. Black DM, Geiger EJ, Eastell R, Vittinghoff E, Li BH, Ryan DS, Dell RM, Adams AL. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. N. Engl. J. Med. 2020;383:743–753.
    doi: 10.1056/NEJMoa1916525pmc: PMC9632334pubmed: 32813950google scholar: lookup
  62. Khan AA, Sándor GKB, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Lentle B. Bisphosphonate Associated Osteonecrosis of the Jaw. J. Rheumatol. 2009;36:478–490.
    doi: 10.3899/jrheum.080759pubmed: 19286860google scholar: lookup
  63. Voss PJ, Stoddart MJ, Bernstein A, Schmelzeisen R, Nelson K, Stadelmann V, Ziebart T, Poxleitner PJ. Zoledronate Induces Bisphosphonate-Related Osteonecrosis of the Jaw in Osteopenic Sheep. Clin. Oral Investig. 2016;20:31–38.
    doi: 10.1007/s00784-015-1468-6pubmed: 25843053google scholar: lookup
  64. Davison MR, Lyardet L, Preliasco M, Yaful G, Torres P, Bonanno MS, Pellegrini GG, Zeni SN. Aminobisphosphonate-Treated Ewes as a Model of Osteonecrosis of the Jaw and of Dental Implant Failure. J. Periodontol. 2020;91:628–637.
    doi: 10.1002/JPER.19-0213pubmed: 31755105google scholar: lookup
  65. Pautke C, Kreutzer K, Weitz J, Knödler M, Münzel D, Wexel G, Otto S, Hapfelmeier A, Stürzenbaum S, Tischer T. Bisphosphonate Related Osteonecrosis of the Jaw: A Minipig Large Animal Model. Bone 2012;51:592–599.
    doi: 10.1016/j.bone.2012.04.020pubmed: 22575441google scholar: lookup
  66. Allen MR, Burr DB. Mandible Matrix Necrosis in Beagle Dogs after 3 Years of Daily Oral Bisphosphonate Treatment. J. Oral Maxillofac. Surg. 2008;66:987–994.
    doi: 10.1016/j.joms.2008.01.038pmc: PMC2464292pubmed: 18423290google scholar: lookup
  67. Larson MJ, Oakes AB, Epperson E, Chew DJ. Medication-Related Osteonecrosis of the Jaw after Long-Term Bisphosphonate Treatment in a Cat. J. Vet. Intern. Med. 2019;33:862–867.
    doi: 10.1111/jvim.15409pmc: PMC6430911pubmed: 30663796google scholar: lookup
  68. Rogers-Smith E, Whitley N, Elwood C, Reese D, Wong P. Suspected Bisphosphate-Related Osteonecrosis of the Jaw in a Cat Being Treated with Alendronate for Idiopathic Hypercalcaemia. Vet. Rec. Case Rep. 2019;7:e000798.
    doi: 10.1136/vetreccr-2018-000798google scholar: lookup
  69. Khan AA, Kaiser S. Atypical Femoral Fracture. CMAJ 2017;189:E542.
    doi: 10.1503/cmaj.160450pmc: PMC5386848pubmed: 28396331google scholar: lookup
  70. Council N, Dyce J, Drost WT, de Brito Galvao JF, Rosol TJ, Chew DJ. Bilateral Patellar Fractures and Increased Cortical Bone Thickness Associated with Long-Term Oral Alendronate Treatment in a Cat. J. Feline Med. Surg. Open Rep. 2017;3:205511691772713.
    doi: 10.1177/2055116917727137pmc: PMC5580850pubmed: 28890795google scholar: lookup
  71. Monzem S, Ballester RY, Javaheri B, Poulet B, Sônego DA, Pitsillides AA, Souza RL. Long-Term Bisphosphonate Treatment Coupled with Ovariectomy in Mice Provokes Deleterious Effects on Femoral Neck Fracture Pattern and Modifies Tibial Shape. Bone Jt. Open. 2020;1:512–519.
    doi: 10.1302/2633-1462.19.BJO-2020-0117.R1pmc: PMC7659644pubmed: 33215149google scholar: lookup
  72. Knych HK, Janes J, Kennedy L, McKemie DS, Arthur RM, Samol MA, Uzal FA, Scollay M. Detection and Residence Time of Bisphosphonates in Bone of Horses. Vet. Diagn. 2022;34:23–27.
    doi: 10.1177/10406387211050049pmc: PMC8689024pubmed: 34918585google scholar: lookup
  73. Riggs CM, Thompson SL, So YM, Wong JKY, Wan TSM, Robinson P, Stewart BD, Ho ENM. Tiludronic Acid Can Be Detected in Blood and Urine Samples from Thoroughbred Racehorses Over 3 Years After Last Administration. Equine Vet. J. 2021;53:1287–1295.
    doi: 10.1111/evj.13395pubmed: 33247964google scholar: lookup
  74. Freedom of Information Summary Original, New Animal Drug Application, NADA 141-420, Tildren, Tiludronate Disodium, Powder for Injection, Horse, for the Control of Clinical Signs Associated with Navicular Syndrome in Horses|FDA Center for Veterinary Medicine|FDA Approved Animal Drug Products. [(accessed on 30 May 2022)]; Available online: https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/918.
  75. Denoix JM, Thibaud D, Riccio B. Tiludronate as a New Therapeutic Agent in the Treatment of Navicular Disease: A Double-Blind Placebo-Controlled Clinical Trial. Equine Vet. J. 2003;35:407–413.
    doi: 10.2746/042516403776014226pubmed: 12880010google scholar: lookup
  76. Bertuglia A, Basano I, Pagliara E, Bottegaro NB, Spinella G, Bullone M. Effect of Intravenous Tiludronate Disodium Administration on the Radiographic Progression of Osteoarthritis of the Fetlock Joint in Standardbred Racehorses. J. Am. Vet. Med. Assoc. 2021;259:651–661.
    doi: 10.2460/javma.259.6.651pubmed: 34448617google scholar: lookup
  77. Katzman SA, Nieto JE, Arens AM, MacDonald MH, Puchalski SM, Galuppo LD, Snyder JR, Maher O, Bell RJW. Use of Zoledronate for Treatment of a Bone Fragility Disorder in Horses. J. Am. Vet. Med. Assoc. 2012;240:1323–1328.
    doi: 10.2460/javma.240.11.1323pubmed: 22607600google scholar: lookup
  78. Arens AM, Barr B, Puchalski SM, Poppenga R, Kulin RM, Anderson J, Stover SM. Osteoporosis Associated with Pulmonary Silicosis in an Equine Bone Fragility Syndrome. Vet. Pathol. 2011;48:593–615.
    doi: 10.1177/0300985810385151pubmed: 21097716google scholar: lookup
  79. Beckstett A. Take-Homes from Veterinarian Roundtable on Bisphosphonate Use in Horses|The Horse. [(accessed on 4 May 2022)]. Available online: https://thehorse.com/184900/take-homes-from-veterinarian-roundtable-on-bisphosphonate-use-in-horses/
  80. Gilday R, Richard H, Beauchamp G, Fogarty U, Laverty S. Abundant Osteoclasts in the Subchondral Bone of the Juvenile Thoroughbred Metacarpus Suggest an Important Role in Joint Maturation. Equine Vet. J. 2020;52:733–742.
    doi: 10.1111/evj.13235pubmed: 31972056google scholar: lookup
  81. Logan AA, Nielsen BD. Training Young Horses: The Science behind the Benefits. Animals 2021;11:463.
    doi: 10.3390/ani11020463pmc: PMC7916178pubmed: 33572461google scholar: lookup
  82. Pepper M, Akuthota V, McCarty EC. The Pathophysiology of Stress Fractures. Clin. Sports Med. 2006;25:1–16.
    doi: 10.1016/j.csm.2005.08.010pubmed: 16324969google scholar: lookup
  83. Romani WA, Gieck JH, Perrin DH, Saliba EN, Kahler DM. Mechanisms and Management of Stress Fractures in Physically Active Persons. J. Athl. Train. 2002;37:306–314.
    pmc: PMC164361pubmed: 16558676
  84. Burr DB. Pharmaceutical Treatments That May Prevent or Delay the Onset of Stress Fractures. 2019. pp. 269–280.
  85. Shima Y, Lars AE, Ae E, Iwasa J, Katsuhiko AE, Ae K, Tomita K. Use of Bisphosphonates for the Treatment of Stress Fractures in Athletes. Knee Surg. Sports Traumatol. Arthrosc. 2009;17:542–550.
    doi: 10.1007/s00167-008-0673-0pubmed: 19048230google scholar: lookup
  86. Ekenman I. Do Not Use Bisphosphonates without Scientific Evidence, Neither in Treatment nor Prophylactic, in the Treatment of Stress Fractures. Knee Surg. Sports Traumatol. Arthrosc. 2009;17:433–434.
    doi: 10.1007/s00167-009-0742-zpubmed: 19238357google scholar: lookup
  87. Breathnach O, Ng K, Spindler KP, Wasserstein DN. Pathophysiology and Epidemiology of Stress Fractures. 2020. pp. 29–39.
  88. Dolan E, Varley I, Ackerman KE, Pereira RMR, Elliott-Sale KJ, Sale C. The Bone Metabolic Response to Exercise and Nutrition. Exerc. Sport Sci. Rev. 2020;48:49–58.
    doi: 10.1249/JES.0000000000000215pubmed: 31913188google scholar: lookup
  89. Logan AA, Nielsen BD, Robison CI, Manfredi JM, Buskirk DD, Schott HC, Hiney KM. Calves, as a Model for Juvenile Horses, Need Only One Sprint per Week to Experience Increased Bone Strength. J. Anim. Sci. 2019;97:3300–3312.
    doi: 10.1093/jas/skz202pmc: PMC6667263pubmed: 31231753google scholar: lookup
  90. Billinghurst RC, Brama PAJ, van Weeren PR, Knowlton MS, McIlwraith CW. Significant Exercise-Related Changes in the Serum Levels of Two Biomarkers of Collagen Metabolism in Young Horses. Osteoarth. Cartil. 2003;11:760–769.
    doi: 10.1016/S1063-4584(03)00152-3pubmed: 13129696google scholar: lookup
  91. Reid IR, Davidson JS, Wattie D, Wu F, Lucas J, Gamble GD, Rutland MD, Cundy T. Comparative Responses of Bone Turnover Markers to Bisphosphonate Therapy in Paget’s Disease of Bone. Bone 2004;35:224–230.
    doi: 10.1016/j.bone.2004.03.023pubmed: 15207761google scholar: lookup
  92. de Lorimier L-P, Fan TM. Bone Metabolic Effects of Single-Dose Zoledronate in Healthy Dogs. J. Vet. Int. Med. 2005;19:924–927.
    doi: 10.1111/j.1939-1676.2005.tb02790.xpubmed: 16355693google scholar: lookup
  93. Statham L, Abdy S, Aspray TJ. Can Bone Turnover Markers Help to Define the Suitability and Duration of Bisphosphonate Drug Holidays?. Drugs Context 2020;9:1–3.
    doi: 10.7573/dic.2020-1-3pmc: PMC7216784pubmed: 32426015google scholar: lookup
  94. Delguste C, Amory H, Doucet M, Piccot-Crézollet C, Thibaud D, Garnero P, Detilleux J, Lepage OM. Pharmacological Effects of Tiludronate in Horses after Long-Term Immobilization. Bone 2007;41:414–421.
    doi: 10.1016/j.bone.2007.05.005pubmed: 17604709google scholar: lookup
  95. McLellan J. Science-in-Brief: Bisphosphonate Use in the Racehorse: Safe or Unsafe?. Equine Vet. J. 2017;49:404–407.
    doi: 10.1111/evj.12682pubmed: 28603949google scholar: lookup
  96. Smith EJ, Little DG, Briody JN, McEvoy A, Smith NC, Eisman JA, Gardiner EM. Transient Disturbance in Physeal Morphology Is Associated With Long-Term Effects of Nitrogen-Containing Bisphosphonates in Growing Rabbits. J. Bone Miner. Res. 2005;20:1731–1741.
    doi: 10.1359/JBMR.050604pubmed: 16160731google scholar: lookup
  97. Martini L, Fini M, Giavaresi G, Giardino R. Comparative Medicine Sheep Model in Orthopedic Research: A Literature Review. Comp. Med. 2001;51:292–299.
    pubmed: 11924786
  98. Kennedy OD, Brennan O, Mahony NJ, Rackard SM, O’Brien FJ, Taylor D, Lee CT. Effects of High Bone Turnover on the Biomechanical Properties of the L3 Vertebra in an Ovine Model of Early Stage Osteoporosis. Spine 2008;33:2518–2523.
    doi: 10.1097/BRS.0b013e318186b292pubmed: 18978592google scholar: lookup
  99. Wu Z, Lei W, Hu Y, Wang H, Wan S, Ma Z, Sang H, Fu S, Han Y. Effect of Ovariectomy on BMD, Micro-Architecture and Biomechanics of Cortical and Cancellous Bones in a Sheep Model. Med. Eng. Phys. 2008;30:1112–1118.
    doi: 10.1016/j.medengphy.2008.01.007pubmed: 18595763google scholar: lookup
  100. Zhang Y, Li Y, Gao Q, Shao B, Xiao J, Zhou H, Niu Q, Shen M, Liu B, Hu K. The Variation of Cancellous Bones at Lumbar Vertebra, Femoral Neck, Mandibular Angle and Rib in Ovariectomized Sheep. Arch. Oral Biol. 2014;59:663–669.
    doi: 10.1016/j.archoralbio.2014.03.013pubmed: 24769217google scholar: lookup
  101. Vernon KL, Riggs L, Coverdale J, Bodine AB, Gibbons J. The Effects of Forced Exercise on Collagen Type II Fragments, Lysyl Oxidase Concentrations, and Total Protein Concentrations in Sera and Synovial Fluid of Lambs. J. Equine Vet. Sci. 2010;30:266–274.
    doi: 10.1016/j.jevs.2010.03.001google scholar: lookup
  102. Tischmacher A, Wilford S, Allen K, Mitchell RD, Parkin T, Denoix J-M. Retrospective Analysis of the Use of Tiludronate in Equine Practice: Safety on 1804 Horses, Efficacy on 343 Horses. J. Equine Vet. Sci. 2022;13:104007.
    doi: 10.1016/j.jevs.2022.104007pubmed: 35577109google scholar: lookup
  103. Delguste C, Doucet M, Gabriel A, Guyonnet J, Lepage OM, Amory H. Assessment of a Bone Biopsy Technique for Measuring Tiludronate in Horses: A Preliminary Study. Can. J. Vet. Res. 2011;75:128–133.
    pmc: PMC3062923pubmed: 21731184
  104. Abboud C, Duveau A, Bouali-Benazzouz R, Massé K, Mattar J, Brochoire L, Fossat P, Boué-Grabot E, Hleihel W, Landry M. Animal Models of Pain: Diversity and Benefits. J. Neurosc. Methods. 2021;348:108997.
    doi: 10.1016/j.jneumeth.2020.108997pubmed: 33188801google scholar: lookup

Citations

This article has been cited 6 times.
  1. Hatunen SL, Anderson JG, Bell CM, Campos HC, Finkelman MD, Shope BH. A retrospective case series on bisphosphonate related osteonecrosis of the jaw in 20 cats. Front Vet Sci 2024;11:1436988.
    doi: 10.3389/fvets.2024.1436988pubmed: 39247125google scholar: lookup
  2. Tippen SP, Metzger CE, Sacks SA, Allen MR, Mitchell CF, McNulty MA. Clinically relevant doses of tiludronate do not affect bone remodelling in pasture-exercised horses. Equine Vet J 2025 Mar;57(2):513-521.
    doi: 10.1111/evj.14119pubmed: 38924597google scholar: lookup
  3. Reis IL, Lopes B, Sousa P, Sousa AC, Caseiro AR, Mendonça CM, Santos JM, Atayde LM, Alvites RD, Maurício AC. Equine Musculoskeletal Pathologies: Clinical Approaches and Therapeutical Perspectives-A Review. Vet Sci 2024 Apr 26;11(5).
    doi: 10.3390/vetsci11050190pubmed: 38787162google scholar: lookup
  4. Vergara-Hernandez FB, Nielsen BD, Popovich JM Jr, Panek CL, Logan AA, Robison CI, Ehrhardt RA, Johnson TN, Chargo NJ, Welsh TH Jr, Bradbery AN, Leatherwood JL, Colbath AC. Clodronate disodium does not produce measurable effects on bone metabolism in an exercising, juvenile, large animal model. PLoS One 2024;19(4):e0300360.
    doi: 10.1371/journal.pone.0300360pubmed: 38626145google scholar: lookup
  5. Ahmad Hairi H, Jayusman PA, Shuid AN. Revisiting Resveratrol as an Osteoprotective Agent: Molecular Evidence from In Vivo and In Vitro Studies. Biomedicines 2023 May 16;11(5).
    doi: 10.3390/biomedicines11051453pubmed: 37239124google scholar: lookup
  6. Nielsen BD. A Review of Three Decades of Research Dedicated to Making Equine Bones Stronger: Implications for Horses and Humans. Animals (Basel) 2023 Feb 22;13(5).
    doi: 10.3390/ani13050789pubmed: 36899647google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.